risk stratification
Hackensack Meridien Health Launches Cancer Risk, Early Detection Program; Eyes Multi-Cancer Testing
Premium
Patients will be offered germline genetic testing after an assessment that includes genetic, lifestyle, and other clinical risk factor analysis.
UK's NICE Expands Tumor Profiling Recommendations for Guiding Adjuvant Chemo in Early Breast Cancer
Previously, NICE recommended EndoPredict, Prosigna, and Oncotype DX for node-negative breast cancer only, but the new guidance includes lymph node-positive disease.
Trial Failure Raises Questions About MRD Testing Utility, but Prognostic Evidence Remains Strong
Presentations at last week's ASCO GI meeting highlighted the ongoing generation of promising data for ctDNA-based minimal residual disease testing despite recent missteps.
Pacific Edge Ramps up Clinical Utility Studies, Commercial Efforts Behind Bladder Cancer Test
Premium
The New Zealand-based diagnostics firm is hoping the coming year will be a tipping point toward new guideline inclusion and broader adoption.
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.